Drugs / HR19042
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials · 1 met primary | ||||||
| Phase 1 | NCT06922305 | Dec 2023 → Jan 2024 | IgA glomerulonephritis, autoimmune hepatitis | Jiangsu HengRui Medicine Co., Ltd. | Completed | Met primary |
| Phase 1 | NCT04887532 | Jul 2021 | IgA glomerulonephritis | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT05476900 | Oct 2022 → Mar 2025 | autoimmune hepatitis | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT05016323 | Sep 2021 → Jun 2024 | IgA glomerulonephritis | Jiangsu HengRui Medicine Co., Ltd. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-04-06 | Jiangsu HengRui Medicine Co., Ltd. | Results WCN 2026高影响力临床试验︱恒瑞新型肠道靶向释放布地奈德制剂HR19042胶囊用于原发性IgA肾病Ⅱ/Ⅲ期研究数据公布 hengrui.com ↗
结果显示， 本研究达到所有主要终点 ，HR19042胶囊可显著降低尿蛋白，并能有效延缓肾功能下降，且安全性与耐受性良好。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-04-06 | Jiangsu HengRui Medicine Co., Ltd. | WCN 2026高影响力临床试验︱恒瑞新型肠道靶向释放布地奈德制剂HR19042胶囊用于原发性IgA肾病Ⅱ/Ⅲ期研究数据公布 hengrui.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HR19042 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05476900 ↗ |
| Route | Oral | “subjects received oral administration of either HR19042 Capsule 16 mg, Tarpeyo® 16 mg, or Budenofalk® 15 mg.” NCT06922305 ↗ |